ImmuPharma (LON:IMM) Stock Price Up 9.5% - Here's What Happened

Key Points

• ImmuPharma plc shares increased by 9.5% on Tuesday, reaching a last traded price of GBX 12.10 ($0.16) after hitting a high of GBX 14.20 ($0.19).
• The company has a market capitalization of £60.47 million, and analysts estimate a projected EPS of -339.0000022 for the current year.
• ImmuPharma specializes in peptide-based therapeutics, with its key program, P140 (Lupuzor™), aimed at treating autoimmune diseases like Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares traded up 9.5% on Tuesday . The company traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). 23,646,498 shares changed hands during trading, an increase of 176% from the average session volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Trading Up 9.5%

The stock has a market cap of £60.47 million, a P/E ratio of -1,359.55 and a beta of 1.53. The firm's 50-day simple moving average is GBX 4.66 and its 200 day simple moving average is GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.